EWTX Stock — Edgewise Therapeutics Inc.: Cash, EV, Pipeline

What they do

Our mission is to discover new medicines that improve the lives of people facing serious muscle disease. At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$45.04

Market cap

$4,931.1M

Cash

$1,228.0M

Enterprise value

$3,703.1M

Balance sheet

Cash	$1,228.0M
Debt	$0.0M
Net cash	$1,228.0M
Enterprise value	$3,703.1M
Basic shares	109.5M shares
Fully diluted shares	135.8M shares
Fully diluted market cap	$6,114.3M
Cash per share	$11.22
Quarterly burn	$42.5M
Cash runway	10.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

108.6M

Pre-funded warrants

0.0M

Options

22.1M

RSUs

1.2M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

3.8M

FDSO

135.8M

Cap table as of 2026-07-31.

Price history

Loading EWTX daily closes…

Loading price history…

Next catalyst

Sevasemten 10 mg · Now - Nov 24, 2026 Now · Phase 2 · Becker Muscular Dystrophy

Recently reported

EDG-15400 Phase 2 Mixed · 2026-10-08

EDG-15400 · heart failure with preserved ejection fraction

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	Sevasemten 10 mg	Phase 2	Becker Muscular Dystrophy	—
Feb 12 - Mar 26 in 14 wks	Sevasemten Dose 1	Phase 2	Duchenne Muscular Dystrophy	—
Apr 12 - May 24 in 5 mo	Sevasemten Dose 1	Phase 2	Duchenne Muscular Dystrophy	—
Jan 12 - Feb 23 in 14 mo	EDG-7500	Phase 2	Hypertrophic Cardiomyopathy	—
Mar 15 - Apr 26 in 53 mo	Sevasemten	Phase 2	Becker Muscular Dystrophy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

EDG-7500

Phase 2 · Active Modality: small molecule

Target cardiac sarcomere modulator (CSM)

Indications

Hypertrophic cardiomyopathy (obstructive and nonobstructive HCM) (Phase 2)

Status note Lead cardiovascular program. Multipart Phase 2 CIRRUS-HCM trial in oHCM and nHCM; topline reported June 2026. Company is now cardiovascular-focused after selling sevasemten to Servier (July 2026).

EDG-15400

Phase 1 · Active Modality: small molecule

Target cardiac sarcomere modulator (CSM)

Indications

Heart failure with preserved ejection fraction (HFpEF) (Phase 1)

Status note Second cardiac sarcomere modulator; Phase 1 in healthy adults (dosing completed); future disease target HFpEF.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Sevasemten Dose 1
Lead indication	Duchenne Muscular Dystrophy
Lead phase	Phase 2
Active trials	6
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05540860	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Duchenne Muscular Dystrophy	—
NCT06100887	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Duchenne Muscular Dystrophy	—
NCT06347159	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Hypertrophic Cardiomyopathy	—
NCT07795814	Phase 2	Recruiting	Sponsor	EWTX	—	Heart Failure With Preserved Ejection Fraction	—
NCT06066580	Phase 2	Enrolling by invitation	Sponsor	EWTX	—	Becker Muscular Dystrophy	—
NCT05291091	Phase 2	Active, not recruiting	Sponsor	EWTX	—	Becker Muscular Dystrophy	—
NCT05257473	Not disclosed	Active, not recruiting	Collaborator	Virginia Commonwealth University	—	Becker Muscular Dystrophy; Muscular Dystrophies; Muscular Dystrophy in Children	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Edgewise Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	15,518,492	no change	11.94%	2026-08-14
RA Capital Management	8,392,730	-2,035,707	2.96%	2026-08-14
Perceptive Advisors	4,373,974	-50,000	2.76%	2026-08-14
Baker Bros. Advisors	3,701,719	-2,874,221	0.75%	2026-08-14
Cormorant Asset Management	2,510,000	-750,000	5.23%	2026-08-14
Braidwell LP	1,996,965	-350,618	3.00%	2026-08-14
DAFNA Capital	226,819	+114,583	1.76%	2026-08-14
ADAR1 Capital Management	143,199	+52,600	0.27%	2026-08-14
Ally Bridge Group	83,300	-77,700	4.36%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

EWTX — Edgewise Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

EWTX — Edgewise Therapeutics Inc.